Abstract
The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.
| Original language | English |
|---|---|
| Pages (from-to) | 785-795 |
| Number of pages | 11 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 125 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Feb 2011 |
Fingerprint
Keywords
- cDNA microarray
- Gene set analysis
- Inflammatory breast cancer
- Receptor subtypes
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. / Iwamoto, Takayuki; Bianchini, Giampaolo; Qi, Yuan; Cristofanilli, Massimo; Lucci, Anthony; Woodward, Wendy A.; Reuben, James M.; Matsuoka, Junji; Gong, Yun; Krishnamurthy, Savitri; Valero, Vicente; Hortobagyi, Gabriel N.; Robertson, Fredika; Symmans, W. Fraser; Pusztai, Lajos; Ueno, Naoto T.
In: Breast Cancer Research and Treatment, Vol. 125, No. 3, 02.2011, p. 785-795.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
AU - Iwamoto, Takayuki
AU - Bianchini, Giampaolo
AU - Qi, Yuan
AU - Cristofanilli, Massimo
AU - Lucci, Anthony
AU - Woodward, Wendy A.
AU - Reuben, James M.
AU - Matsuoka, Junji
AU - Gong, Yun
AU - Krishnamurthy, Savitri
AU - Valero, Vicente
AU - Hortobagyi, Gabriel N.
AU - Robertson, Fredika
AU - Symmans, W. Fraser
AU - Pusztai, Lajos
AU - Ueno, Naoto T.
PY - 2011/2
Y1 - 2011/2
N2 - The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.
AB - The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.
KW - cDNA microarray
KW - Gene set analysis
KW - Inflammatory breast cancer
KW - Receptor subtypes
UR - http://www.scopus.com/inward/record.url?scp=79151482682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79151482682&partnerID=8YFLogxK
U2 - 10.1007/s10549-010-1280-6
DO - 10.1007/s10549-010-1280-6
M3 - Article
VL - 125
SP - 785
EP - 795
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 3
ER -